On September 13, 2023 AimedBio reported to have received equity investment from the "Life Science Fund", an investment fund created by Samsung Biologics, Samsung C&T, and Samsung Bioepis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– It is Samsung’s fourth investment through the "Life Science Fund", but the first case as domestic investment.

– They will be collaborating on ADC toolbox co-development and CDO business of AMB001, a KDDF grant-receiving platform.

(Press release, AimedBio, SEP 13, 2023, View Source;s_keyword=&s_where=&start=10 [SID1234656920])